Company / Capital Expenditures
Haemonetics Capital Expenditures History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$39.3M
FY2024
5-year range
$38.1M / $191.3M
FY2020-FY2024
Trend
+3.0%
vs FY2023
Sector context
#82 of 145
Health Care
What the data says
At $39M, Haemonetics's capital expenditures ranks #82 of 145 in the Health Care sector. Capital Expenditures has fluctuated over the past 9 years, ranging from $37M in FY2020 to $191M in FY2022.
Based on SEC 10-K filings.
$39M in FY2024 with a 5-year CAGR of -4.2%.
Declined from $191M to $39M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -25.9%
- 5-Year CAGR
- -4.2%
- 10-Year CAGR
- -
Sector benchmark
#82 of 145 in Health CareTop 57% of 145This company $39.3M Sector average $268.6M
▼
-85.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.2%, indicating a declining trend.
- In FY2024, capital expenditures increased 3.0% year-over-year.
- Ranks #82 out of 145 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $39.3M | +3.0% |
| FY2023 | $38.1M | -80.1% |
| FY2022 | $191.3M | +98.2% |
| FY2021 | $96.5M | +160.6% |
| FY2020 | $37.0M | -24.0% |
| FY2019 | $48.8M | -59.0% |
| FY2018 | $119.0M | +59.0% |
| FY2017 | $74.8M | -1.8% |
| FY2016 | $76.1M | -25.7% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026